试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-04-26
Safety and Efficacy of Corneal Collagen Cross-linking Following LASIK for Treatment of Hyperopia and Hyperopic Astigmatism
编号:NCT01893359登记状态:提前终止企业 / 申办者:Glaukos Corporation
药物 / 成分:riboflavin ophthalmic solution, 0% dextran、UVA Irradiation (30 mW/cm2 for 2 minutes continuous UVA)、UVA Irradiation (30 mW/cm2 for 3 minutes pulsed UVA with an on/off cycle of 2 seconds UVA on/1 second UVA off)、Laser-assisted in situ keratomileusis
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-04-26
Safety and Efficacy of Corneal Collagen Cross-Linking in Eyes With Keratoconus
编号:NCT01972854登记状态:提前终止企业 / 申办者:Glaukos Corporation
药物 / 成分:riboflavin solution、placebo solution、KXL System
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-04-26
Oral Vancomycin for Preventing Clostridium Difficile Recurrence
编号:NCT03200093登记状态:提前终止企业 / 申办者:Rochester General Hospital
药物 / 成分:Oral Vancomycin、Placebo
登记的停止原因(原文):Low recruitment due to few eligible participants.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-04-26
Vemurafenib Plus Cobimetinib in Advanced or Metastatic Melanoma Patients
编号:NCT03224208登记状态:提前终止企业 / 申办者:Fondazione Melanoma Onlus
药物 / 成分:Vemurafenib、Cobimetinib
登记的停止原因(原文):low enrolment rate
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-04-26
Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis
编号:NCT03259308登记状态:提前终止企业 / 申办者:Shire
药物 / 成分:Ontamalimab、Placebo
登记的停止原因(原文):Sponsor decision to discontinue the SHP647 (ontamalimab) clinical trial development program for inflammatory bowel diseases (IBD) early.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-04-26
Efficacy of Candidate Influenza Vaccine MVA-NP+M1 in Adults
编号:NCT03880474登记状态:提前终止企业 / 申办者:Barinthus Biotherapeutics
药物 / 成分:MVA-NP+M1、Saline
登记的停止原因(原文):The trial is being stopped for futility. Season 2 cancelled.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-04-23
Using Cinacalcet to Treat the Hypophosphatemia of Early Kidney Transplant
编号:NCT01011114登记状态:提前终止企业 / 申办者:Montefiore Medical Center
药物 / 成分:Cinacalcet、Placebo
登记的停止原因(原文):Study was not renewed with the IRB
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-04-23
Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia
编号:NCT01125293登记状态:提前终止企业 / 申办者:Dana-Farber Cancer Institute
药物 / 成分:Everolimus、Rituximab、Bortezomib
登记的停止原因(原文):Per protocol, Phase II is to be terminated early if a less than 5% of the Phase II participants observe a Very Good Partial Response or Better in the first 23 participants enrolled to Phase II.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-04-23
Study Of Tasquinimod In Asian Chemo-Naïve Patients With Metastatic Castrate-Resistant Prostate Cancer
编号:NCT02057666登记状态:提前终止企业 / 申办者:Ipsen
药物 / 成分:Tasquinimod、Placebo
登记的停止原因(原文):Development of tasquinimod in prostate cancer discontinued
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-04-23
Trial of Nortriptyline and Topiramate in the Initial Treatment of Vestibular Migraine
编号:NCT02169830登记状态:提前终止企业 / 申办者:St. Louis University
药物 / 成分:nortriptyline、Topiramate、Diet Modification
登记的停止原因(原文):Lack of enrollment
查看官方原始记录 ↗